Skip to content

Author

Jing-Jing Lan

We have 1 of 11 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment

A health technology assessment framework is applied to systematically evaluate the use of PCSK9 inhibitors in patients with ASCVD and finds that evolocumab demonstrates relative advantages in lipid-lowering efficacy, cardiovascular outcomes, and economic value for patients with ASCVD.

Jing-Jing Lan, Yu-Lan Qiu, Shuaijian Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.